UPC Analytics
DEEN
Übersicht · Eingereicht: —

ACT_597355/2023

METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

VerletzungHauptverletzungsklageDusseldorf LDInfringement Action—
ÜbersichtEntscheidungenBegründungZitateDokumenteZeitverlauf
Parteien

Kläger

  • Sanofi Biotechnologies SAS
  • Regeneron Pharmaceuticals Inc.
Vertreter: Niels Hölder (HOFFMANN EITLE PartmbB); Mike Gruber (HOFFMANN EITLE PartmbB); Michael Pfeifer (HOFFMANN EITLE PartmbB); Daniel Wise (Carpmaels & Ransford LLP); Agathe Michel-De Cazotte (Carpmaels & Ransford LLP)

Beklagte

Vertreter: null
Richter
  • Ronny ThomasPresiding judge
  • Anna Bérénice ThomLegally qualified judge
  • András Ferenc KupeczLegally qualified judge
  • Xavier Thomas Olivier Dorland-GalliotTechnically qualified judge
Patente
  • EP3536712
CPC-Codes: A61K39/3955, C07K2317/76, A61P9/00, A61P43/00, A61P27/02, C07K2317/21, A61P7/00, C07K16/40, A61K2039/505, A61P11/00, A61P3/06, A61P9/10

Technologiebereich: Pharmaceuticals · Antibody/Biologics

Sektor: Organic Chemistry

Ausgang
Nicht verletztNicht verletzt
Eingereicht: —
Erste Entscheidung: 13. Mai 2025
Sprache: —

The Düsseldorf Local Division dismissed Sanofi and Regeneron's infringement action and Amgen's counterclaim for revocation concerning EP3536712 (a second medical use patent for evolocumab in paediatric patients), finding no infringement of the second medical use claim and that the counterclaim for revocation was also unfounded, with each side bearing the costs of the proceedings they lost.

Ansprüche
Streitigall
Nicht verletztall
Hinweise: Düsseldorf LD dismissed infringement action on second medical use claim of EP3536712 B1 and dismissed counterclaim for revocation; no specific claim numbers enumerated in operative order.